News
Advancing Therapeutic Knowledge of Genetic Influence in ALS: Matthew B. Harms, MD
February 19th 2025The associate professor of neurology at Columbia University gave clinical insight on what neurologists and other neuromuscular specialists can expect from the ALS/frontotemporal dementia track at this year’s MDA Clinical & Scientific Conference. [WATCH TIME: 3 minutes]
Solid Reports Positive Data for SGT-003 Gene Therapy in Phase 1/2 Trial of Duchenne
February 18th 2025After 90 days of treatment, investigators observed positive findings on microdystrophin expression, as well as reductions in markers of muscle injury and stress, and muscle breakdown and dystrophic regeneration.
ALS, Genetics, and New Horizons: What to Expect at the 2025 MDA Conference
February 18th 2025Matthew B. Harms, MD, an associate professor of neurology at Columbia University Irving Medical Center, an MDA Care Center, gave clinical insights on the advances in ALS genetic research and what clinicians can expect from the ALS/FTD track at the 2025 MDA Clinical & Scientific Conference.
Expanding the Development of Cell Therapy for Muscular Dystrophy: Rita Perlingeiro, PhD
February 18th 2025The Lillehei professor in stem cell and regenerative cardiovascular medicine at the University of Minnesota talked about the potential of investigating inducted pluripotent stem cells in neuromuscular diseases at MDA’s 2025 conference. [WATCH TIME: 8 minutes]
Meta-Analysis Reveals Patients With Epilepsy at Increased Risk for Psychiatric Disorders
February 18th 2025Findings showed that patients with epilepsy were significantly more likely to experience a range of psychiatric disorders, including depression, anxiety, and substance use disorders, compared with those without the condition.
Key Considerations When Incorporating Stroke Trial Data Into Clinical Practice: J Mocco, MD, MS
February 17th 2025The director of the Cerebrovascular Center at Mount Sinai highlighted key differences in patient selection criteria and trial designs that may influence how stroke treatment data is applied in clinical practice. [WATCH TIME: 5 minutes]
Evolving Parkinson Disease Care in the Digital Age of Neurology: Sheryll Baltazar, NP-C
February 17th 2025The nurse practitioner at the Parkinson’s and Movement Disorders Center at Stony Brook Medicine discussed the increasing role of artificial intelligence in neurology, specifically movement disorders. [WATCH TIME: 5 minutes]
New Functional MRI Model Shows High Accuracy in Differentiating Between MS and NMOSD
February 16th 2025A newly developed advanced fMRI-based classification model demonstrated efficacy in distinguishing multiple sclerosis from neuromyelitis optica spectrum disorder, potentially having the ability to improve diagnostic accuracy.
Engaging the Clinical and Patient DMD Community at the 2025 FUTURES Conference: Heather Medlin, MSW
February 16th 2025The associate vice president of community outreach at CureDuchenne talked about events like the 2025 FUTURES National Conference that aim to bring individuals from the Duchenne community together. [WATCH TIME: 6 minutes]
NeurologyLive® Brain Games: February 16, 2025
February 16th 2025Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on chronic demyelinating inflammatory polyneuropathy (CIDP).
Cerebrospinal Fluid Lipids Shows Promise as Biomarkers for Differentiating NMOSD and MS
Published: February 15th 2025 | Updated: February 18th 2025Cerebrospinal fluid lipid profiling revealed potential biomarkers for distinguishing NMOSD from MS and tracking disease activity, offering new insights into neuroinflammatory disease monitoring.
Understanding the Process Behind Treatment Selection in NMOSD: Tammy Smith, MD, PhD
February 14th 2025The assistant professor in the neurology department at the University of Utah in Salt Lake City provided a clinical overview of the new and old therapies for NMOSD, and how clinicians should go about choosing for their patients. [WATCH TIME: 6 minutes]
Advancements in Mechanical Thrombectomy and Imaging: A Stroke Neurologist’s Perspective
February 14th 2025Andrei Alexandrov, MD, chair of the department of neurology at the University of Arizona College of Medicine, covered the latest advancements in stroke care from ISC 2025, from expanding thrombectomy indications to evolving imaging techniques.
Using Integrative Neurology and Personalized Medicine to Transform Care in 2025: Sushma Kola, MD
February 14th 2025The director of Integrative Neurosciences at Allegheny Health Network talked about integrative neurology, personalized medicine, and emerging diagnostic tools that enhance patient-centered care. [WATCH TIME: 5 minutes]
Study Identifies Key Inflammatory Markers in Pediatric MOGAD, Suggesting New Therapeutic Targets
February 13th 2025A recent study reported significantly elevated cerebrospinal fluid inflammatory markers in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease during acute phases.
Reducing OFF Time in Parkinson Disease With SPN-830 Infusion Therapy: Julie Pilitsis, MD, PhD, MBA
February 13th 2025The chair of neurosurgery at the University of Arizona talked about the newly approved infusion therapy that offers continuous medication delivery to improve both motor and non-motor symptoms in Parkinson disease. [WATCH TIME: 5 minutes]
FDA Grants Fast Track Designation to Promising Multiple System Atrophy Agent Amlenetug
February 13th 2025Amlenetug, a human monoclonal antibody that recognizes and binds to all major forms of extracellular α-synuclein, is currently being assessed in a large-scale phase 3 trial to determine its therapeutic potential as a treatment for MSA.
